Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06979362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06979362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Recruiting
Start date
June 27, 2025
Completion date
July 25, 2028
Enrollment
200 (estimated)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure